Long-term issues after Immunosuppressive therapy for Aplastic Anemia | Aplastic Anemia and MDS International Foundation

Long-term issues after Immunosuppressive therapy for Aplastic Anemia

Journal Title: 
Curr Drug Targets
Primary Author: 
de Fontebrune FS
Author(s): 
de Fontebrune FS, Socié G
Original Publication Date: 
Monday, May 2, 2016

Survival rate using antithymocyte globulins and cyclosporine in patients with aplastic anemia now ranges 70-80%. However, patients with aplastic anemia are faced with significant problems, on the long-term. These long-term issues can be broadly divided on three topics; cyclosporine dependence, relapse of the original disease, and evolution of aplastic anemia to a malignant clonal disease. These long-term issues are briefly reviewed here as well as recent data on the use of next generation sequencing.

Bone Marrow Diseases: